Wednesday, September 14, 2011

Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases.

Methods Mol Biol. 2011;793:495-508.

Soragni E, Xu C, Cooper A, Plasterer HL, Rusche JR, Gottesfeld JM.
Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA, USA.

Keywords: neurodegenerative diseases, aberrant gene expression, pimelic o-aminobenzamide histone deacetylase (HDAC) inhibitors, Friedreich's ataxia (FRDA), Huntington's disease (HD), cellular models.

Superando la barrera hematoencefálica

Traduccion de EurekAlert!.org, 13 septiembre 2011, que se encuentra en Bitnavegantes


"Por primera vez, los investigadores descubrieron que, cuando los receptores de adenosina se activan en las células que forman la barrera hematoencefálica, se abre una puerta de entrada a través dicha barrera."

Breaching the blood-brain barrier

EurekAlert!, Public release date: 13-Sep-2011

"For the first time, the researchers discovered that when adenosine receptors are activated on cells that comprise the blood-brain barrier, a gateway into the blood-brain barrier can be established."

Adenosine Receptor Signaling Modulates Permeability of the Blood–Brain Barrier

The Journal of Neuroscience, 14 September 2011, 31(37): 13272-13280; doi: 10.1523/​JNEUROSCI.3337-11.2011

Aaron J. Carman, Jeffrey H. Mills, Antje Krenz, Do-Geun Kim, and Margaret S. Bynoe
Department of Microbiology and Immunology, Cornell University, College of Veterinary Medicine, Ithaca, New York 14853

Acute myocardial infarction after botulinum toxin injection.

QJM (2011) 104(7): 615-616

B.E. Stähli, L. Altwegg, T.F. Lüscher and R. Corti
Department of Cardiology, Cardiovascular Center, University Hospital Zürich, Zürich, Switzerland

Keywords: Friedreich ataxia, ventricular fibrillation, botulinum toxin A, neurogenic bladder dysfunction,thrombotic occlusion.